Developing biomarkers for cerebral amyloid angiopathy trials: do potential disease phenotypes hold promise? - authors' reply.
MGH Stroke Research Center, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: sgreenberg@mgh.harvard.edu.
Steven M
SM
Greenberg
Division of Clinical Neurosciences, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.
Rustam
R
Al-Shahi Salman
Brain Centre Rudolf Magnus, University Medical Center of Utrecht, Utrecht, Netherlands.
Geert Jan
GJ
Biessels
Department of Radiology, Leiden University Medical Center, Leiden, Netherlands.
Mark
M
van Buchem
Department of Neurology, Universite Lille Nord de France, Lille University Hospital, Lille, France.
Charlotte
C
Cordonnier
Department of Neurology, Department of Radiology, and Department of Biomedical Engineering, Washington University School of Medicine, St Louis, MO, USA.
Jin-Moo
JM
Lee
Department of Neurology, Vall d'Hebron University Hospital and Research Institute, Autonomus University of Barcelona, Barcelona, Spain.
Joan
J
Montaner
Department of Pathology and Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Julie A
JA
Schneider
Hotchkiss Brain Institute, University of Calgary, Calgary, AB, Canada.
Eric E
EE
Smith
Department of Radiology and Epidemiology, Erasmus University Medical Center, Rotterdam, Netherlands.
Meike
M
Vernooij
UCL Institute of Neurology, London, UK.
David J
DJ
Werring
D015415:Biomarkers; D016657:Cerebral Amyloid Angiopathy / Q000473:pathology* / Q000628:therapy*; D006801:Humans
D015415:Biomarkers